1. Breaking Down the CVOTs

2. Why CVOTs and What Do They Mean?

3. Increased Risk of Mortality and CVD in T2D

4. Completed and Ongoing CVOTs Study Populations

5. Published CVOTs Different Populations

6. Published DPP-4 Inhibitor CVOTs Comparison of Results

7. GLP-1 RA CVOTs Comparison of Results

8. SGLT2 Inhibitor CVOT Results From EMPA-REG OUTCOME

9. CANVAS Study Population

10. EMPA-REG OUTCOME and CANVAS CVOTs Comparison of Results

11. CANVAS Canagliflozin Is Renoprotective

12. Implications for Clinical Practice RCTs vs Real World

13. CANVAS: Safety of Canagliflozin

14. Closing Comments

15. Abbreviations

16. Abbreviations (cont)